8,883 Shares in Zimmer Biomet Holdings, Inc. $ZBH Purchased by Bryn Mawr Trust Advisors LLC

Bryn Mawr Trust Advisors LLC bought a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 8,883 shares of the medical equipment provider’s stock, valued at approximately $765,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. PNC Financial Services Group Inc. grew its holdings in shares of Zimmer Biomet by 9.4% during the fourth quarter. PNC Financial Services Group Inc. now owns 161,195 shares of the medical equipment provider’s stock worth $14,495,000 after buying an additional 13,883 shares in the last quarter. Morningstar Investment Management LLC grew its holdings in Zimmer Biomet by 235.4% in the 4th quarter. Morningstar Investment Management LLC now owns 57,865 shares of the medical equipment provider’s stock valued at $5,204,000 after buying an additional 40,610 shares during the period. Northwestern Mutual Wealth Management Co. increased its stake in shares of Zimmer Biomet by 257.2% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 34,370 shares of the medical equipment provider’s stock valued at $3,091,000 after acquiring an additional 24,748 shares during the last quarter. Robertson Stephens Wealth Management LLC acquired a new stake in shares of Zimmer Biomet in the fourth quarter worth approximately $1,131,000. Finally, CIBC Asset Management Inc increased its position in Zimmer Biomet by 67.6% during the fourth quarter. CIBC Asset Management Inc now owns 46,516 shares of the medical equipment provider’s stock worth $4,183,000 after purchasing an additional 18,769 shares during the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Analyst Upgrades and Downgrades

ZBH has been the subject of a number of research reports. Citizens Jmp lowered their price target on Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating for the company in a research report on Wednesday, April 29th. Wells Fargo & Company decreased their price target on shares of Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 29th. Sanford C. Bernstein upped their target price on Zimmer Biomet from $91.00 to $93.00 and gave the stock a “market perform” rating in a research report on Thursday, August 6th. BMO Capital Markets reaffirmed a “market perform” rating and issued a $96.00 price objective on shares of Zimmer Biomet in a research report on Thursday, August 6th. Finally, Stifel Nicolaus lifted their price target on shares of Zimmer Biomet from $105.00 to $110.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $104.42.

Insiders Place Their Bets

In related news, insider Sang Yi sold 5,000 shares of the stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $82.64, for a total transaction of $413,200.00. Following the sale, the insider owned 27,251 shares in the company, valued at $2,252,022.64. This represents a 15.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.28% of the stock is currently owned by company insiders.

Zimmer Biomet Trading Up 1.0%

NYSE:ZBH opened at $100.52 on Friday. The company has a market cap of $19.17 billion, a PE ratio of 24.46, a P/E/G ratio of 3.17 and a beta of 0.45. The business’s 50 day moving average is $91.51 and its two-hundred day moving average is $90.54. The company has a quick ratio of 0.94, a current ratio of 1.69 and a debt-to-equity ratio of 0.50. Zimmer Biomet Holdings, Inc. has a 52 week low of $79.12 and a 52 week high of $108.29.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.01 by $0.06. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The business had revenue of $2.18 billion for the quarter, compared to analyst estimates of $2.13 billion. During the same period in the prior year, the company posted $2.07 EPS. The business’s revenue was up 4.8% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. On average, analysts predict that Zimmer Biomet Holdings, Inc. will post 8.53 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, July 31st. Investors of record on Thursday, June 25th were given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend was Thursday, June 25th. Zimmer Biomet’s dividend payout ratio is currently 23.36%.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.